CompanyCGONNasdaqDallas, TX

CG Oncology, Inc.

CG Oncology develops immunotherapies for bladder cancer.

SEC EDGAR ClinicalTrials.gov cgoncology.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 6Latest story

August 2026

CG Oncology reports Q2 2026 results, flags near-term PIVOT-006 data

Aug 6Clinical readoutCG Oncology, Inc.

CG Oncology expands stock sale program to $1.05 billion

Aug 6FinancingCG Oncology, Inc.